-
ASCO-GU Interview | Dr. Pengfei Shen Interprets PROpel Study, Shares Genetic Testing to Guide Precise Treatment of Prostate Cancer
Oncology Frontier : This ASCO-GU Symposium published several latest researches related to PARP inhibitors. Among them, the PROpel study revealed the efficacy of olaparib in combination with abiraterone compared to…
-
2024 CASH丨Professor Jinghui Zhang：Monitoring clonal hematopoiesis in pediatric patients helps improve long-term prognosis
Clonal hematopoiesis typically refers to the proliferation of hematopoietic stem cells due to genetic mutations, which is also the basis for various hematologic diseases; monitoring clonal hematopoiesis helps in early detection of hematologic malignancies. At the Fourth China Hematology Development Conference (CASH) held recently, Professor Jinghui Zhang from St. Jude Children’s Research Hospital shared a…
-
2024 CASH | Professor Ying Wang : Immunotherapy Brings Strong Vitality to the Treatment of Adult R/R ALL
The Fourth China Hematology Development Conference was held in Tianjin from January 5 to 7, 2024. Themed “Broad Hematology, Public Health, and Overall Well-being,” the conference centered around the core development directions of hematology, as well as major disciplinary issues faced in basic hematology research, translation, and clinical diagnosis and treatment in the new era.…
-
ASCO-GU Interview | Dr. Fufu Zheng Shares Advances in First-Line PARPi Treatment and Genetic Testing for mCRPC
Oncology Frontier: Numerous studies targeting the HRR pathway in prostate cancer emerged at this conference. For instance, the PROpel study on olaparib combined with NHA revealed data for the HRRm…
-
ASCO-GU Interview | Dr. Shun Zhang: The Value and Development of Genetic Testing in Precision Treatment of Prostate Cancer
Oncology Frontier: The research presented at this ASCO-GU prostate cancer session highlights the increasing importance of genetic testing in prostate cancer, guided by molecular typing for precision targeted therapy. Based…
-
2024 CASH | Professor Tao Cheng: Misaligned Development, Collaborative Innovation – A Discussion on High-Quality Development in Hematology Against the Backdrop of the Innovation Era
The Fourth China Hematology Development Conference was held in Tianjin from January 5th to 7th, 2024. Themed “Broadening Hematology, Healthcare, and Wellness,” the conference focused on the core development directions of the hematology discipline and engaged in discussions and sharing of hot topics and cutting-edge issues in basic hematology research, translation, and clinical diagnosis and…
-
ASCO-GU Interview | Dr. Qiang Wei: Embracing the Era of Precision Treatment, Offering Personalized Treatment Through Multidisciplinary Management
Editor’s Note: Prostate cancer is the most common “silent killer” threatening men’s health worldwide, with traditional treatments primarily involving surgery, radiation therapy, chemotherapy, and hormonal therapy. In recent years, the…
-
ASCO-GU Interview | Dr. Junlong Zhuang Interprets the BRCAAway Study and Real-World Genetic Testing in Advanced Prostate Cancer
Oncology Frontier: BRCA mutations are the most clinically significant type of mutation in prostate cancer. At this ASCO-GU, we saw the presentation of treatment efficacy results from the BRCAAway study,…
Connecting Medical Expertise through Media